Clinical Trial

Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

Study acronym: TriComB
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC patients who are deemed not eligible for intensive chemotherapy (part 2, expansion phase).
Protocol Amendment History 1 change
minor Completion pushed: 2026-03 -> 2026-11 2026-05-21
Trial Details
NCT Number NCT04564898
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Conditions Colorectal Cancer Metastatic
Enrollment 48 participants
Start Date 2022-01-25
Primary Completion 2024-05-29 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-20